Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 5/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 4/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CCNH | P51946 | 1/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.32 |
| ▸ | MGMT | P16455 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618832 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL11200783 | 0.78 | ALDH1A1 (0.58) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL28126988 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| Iodide SCHEMBL28673351 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| Water SCHEMBL28488923 | 0.76 | ALDH1A1 (0.56) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL28623710 | 0.75 | ALDH1A1 (0.44) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL27658630 | 0.75 | ALDH1A1 (0.50) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL1797752 | 0.74 | — | — | |
| SCHEMBL5138814 | 0.74 | ALDH1A1 (0.53) | ALDH1A1KDM4ERXFP1CDK2PAK1 | |
| SCHEMBL1079075 | 0.73 | ALDH1A1 (0.49) | ALDH1A1KDM4ERXFP1CDK2PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | claimed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | claimed |
| US-9878050-B2 | Delivery of agents using interfering nanoparticles | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170182177-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-06-29 | — | — | US | disclosed |
| US-9526693-B2 | Delivery of agents using interfering nanoparticles | Sanford-Burnham Medical Research Inslilute (US) | 2016-12-27 | — | — | US | disclosed |
| US-20110263514-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011116152-A2 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD -BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
| US-7951784-B2 | modified small interfering RNAs (siRNAs) that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA; gene expression inhibition; for treating amyotrophic lateral sclerosis associated with the activity of a protein specified by a target mRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1986699-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1986609-A2 | RNA SILENCING AGENTS FOR USE IN THERAPY AND NANOTRANSPORTERS FOR EFFICIENT DELIVERY OF SAME | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080125386-A1 | RNA interference agents for therapeutic use | UNIVERSTIY OF MASSACHUSETTS (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2007092182-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007089607-A2 | RNA SILENCING AGENTS FOR USE IN THERAPY AND NANOTRANSPORTERS FOR EFFICIENT DELIVERY OF SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | disclosed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125386-A1 | RNA interference agents for therapeutic use | HNRNPH1, SNRPE, RNASEH1 | ALDH1A1 478/4885KDM4E 3231/4885RXFP1 4060/4885 |
| US-20170182177-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SNRPE, SNRPF, SNRPA | ALDH1A1 3373/4885KDM4E 4086/4885RXFP1 1707/4885 |
| US-20110263514-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SNRPE, SNRPF, SNRPA | ALDH1A1 3373/4885KDM4E 4086/4885RXFP1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.